Montelukast Denk (Montelukast)

• Montelukast acts on the leukotriene pathway to manage several respiratory conditions.
• Asthma: improves control of chronic airway inflammation and reduces frequency of exacerbations.
• Allergic rhinitis: alleviates nasal congestion, sneezing and itching caused by allergic triggers.
• Exercise‑induced bronchoconstriction: prevents airway narrowing during or after physical activity.

• Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and other cysteinyl leukotrienes from binding to airway smooth‑muscle and inflammatory cells. By inhibiting this receptor, the drug reduces bronchoconstriction, mucus secretion, vascular permeability and eosinophilic inflammation, thereby improving airway function and alleviating allergic symptoms. The antagonism is dose‑dependent and contributes to long‑term control of chronic airway disease when used as part of a prescribed regimen.

Montelukast may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache
• Abdominal pain
• Cough
• Nausea
• Dizziness
• Fatigue

Serious or Rare Side Effects

• Allergic reactions such as rash, angioedema, or anaphylaxis
• Mood changes including depression, anxiety, or suicidal thoughts
• Elevated liver enzymes or hepatitis
• Severe skin reactions like Stevens‑Johnson syndrome
• Eosinophilic granulomatosis with polyangiitis
• Unexplained fever or systemic hypersensitivity

• Before prescribing Montelukast, clinicians should consider several precautionary measures to ensure patient safety.
• Assess asthma control: ensure patient is on appropriate baseline therapy before adding montelukast.
• Monitor for neuropsychiatric events: watch for mood changes, depression, or suicidal ideation during treatment.
• Evaluate hepatic function: consider baseline liver enzymes in patients with liver disease or concomitant hepatotoxic drugs.
• Avoid use in patients with known hypersensitivity to montelukast or any excipients in the formulation.
• Store at room temperature: keep below 25°C, protect from moisture and light in original packaging.

Montelukast can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Phenobarbital: may reduce montelukast plasma concentrations, lowering effectiveness.
• Rifampin: enzyme induction can decrease drug levels and therapeutic response.
• Ketoconazole: may increase exposure, raising risk of adverse effects.
• Carbamazepine: can lower montelukast concentrations, compromising control.
• St. John’s wort: may diminish drug effectiveness through metabolic induction.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of anticoagulant effect; monitor INR.
• Theophylline: possible additive bronchial effects; observe respiratory status.
• Beta‑agonists: monitor for overlapping respiratory actions.
• ACE inhibitors: watch for cough exacerbation when combined.
• Antidepressants: observe for overlapping neuropsychiatric symptoms.